Log in

AGEN Agenus Inc. NASDAQ · United States

Agenus (AGEN) news AGEN class action news

Latest Agenus news

  1. Legal

    Agenus securities class action dismissed, plaintiff appeals; SEC closes investigation

    The District of Massachusetts dismissed In re Agenus Inc. Securities Litigation on March 24, 2026. The lead plaintiff appealed to the First Circuit, where briefing began in June. Derivative suits remain stayed.

  2. Debt Financing

    Agenus extends maturity of $5.09 million in notes

    Agenus pushed back the maturity of $5.09 million of 2015 notes by eight months, to February 18, 2027, and extended the expiration of earlier warrants to June 25, 2031. The filing does not describe new cash from the deal.

  3. Mergers

    Agenus completes $75.0 million manufacturing asset sale to Zydus and $16.0 million stock sale

    Agenus received $75 million, less certain expenses, for its manufacturing operations, and sold 2,133,333 shares to a Zydus affiliate at $7.50 each. Up to $50 million in further payments depends on orders for its BOT+BAL drug product.

  4. Financings

    Agenus takes up to $10,000,000 loan from Zydus, pledges 822,910 MiNK shares

    The note bears interest at 3.81% a year and is tied to the closing of an asset and stock purchase deal the companies signed on June 3, 2025.

  5. Financings

    Agenus extends $10.5 million of 2015 notes to July 2026 and reprices warrants at $3.25

    The interest rate on the notes rises from 8% to 9%, and Agenus will grant a subordinate mortgage on properties owned by Agenus West, LLC. New warrants cover 67,500 shares.

Agenus annual financials

LineFY2025FY2024
Research and development$79.3 million$155.5 million
Cash from operations-$77.2 million-$158.3 million
Cash and equivalents$3.0 million$40.4 million

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $18.7 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Agenus

Is there a class action against Agenus?

Our latest story on this, dated Aug 7, 2026: "Agenus securities class action dismissed, plaintiff appeals; SEC closes investigation". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of Agenus?

Agenus Inc. trades under the ticker AGEN on NASDAQ.

Where is Agenus listed?

Agenus Inc. is listed on NASDAQ. Our directory also records these other listings: BX:AGEN; GETTEX:AJ8; LSX:A403RK.

What is the SEC CIK of Agenus?

The SEC Central Index Key (CIK) for Agenus Inc. is 1098972. Its filings are on SEC EDGAR.

How many shares does Agenus have outstanding?

45,020,407 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-07.

Which country or territory is Agenus listed under?

Our directory records Agenus Inc. under United States.

What does Agenus do?

Our directory classifies Agenus Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Agenus?

The ISIN recorded for Agenus Inc. is US00847G8042.

Does aibio.space cover Agenus?

aibio.space lists Agenus Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Agenus incorporated?

SEC records list its state or country of incorporation as DE.

How much does Agenus spend on research and development?

$79.3 million in the fiscal year ended Dec 31, 2025, per its annual report.

How much cash does Agenus have?

$18.7 million in cash at Jun 30, 2026, per its 10-Q.

What is the latest Agenus (AGEN) stock news?

Our latest story on Agenus, dated Aug 12, 2026: "Agenus extends Ocean 1181 loan maturity to November 2029". The loan principal stays at $24,750,000 and the rate stays at 13.0%. The $247,500 extension fee is paid half in cash and half in shares. Source.

What is Agenus's latest stock offering or financing news?

Our latest financing story, dated Oct 9, 2025: "Agenus takes up to $10,000,000 loan from Zydus, pledges 822,910 MiNK shares". The note bears interest at 3.81% a year and is tied to the closing of an asset and stock purchase deal the companies signed on June 3, 2025. Source.

Who were the underwriters or placement agents on Agenus's offering?

From our story: Agenus Inc. said that on August 12, 2026, its subsidiary Agenus West, LLC, as borrower, and Agenus, as guarantor, entered into a Second Loan Modification Agreement with Ocean 1181 LLC, the lender. Source.

Investor discussion: Agenus

Members talk about Agenus (AGEN). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Agenus, newest first. Each line links the filing it comes from.

  1. Financings

    Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02). Source

  2. Financings

    Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). Source

  3. Legal

    Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01). Source

  4. Distress

    Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source

  5. Mergers

    Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,3.02,7.01,9.01). Source

  6. Financings

    Reported a financing. SEC Form 8-K (Items 1.01,2.03). Source

  7. Financings

    Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). Source

  8. Distress

    Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source

  9. Legal

    Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. Source

  10. Financings

    Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). Source

  11. Distress

    Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source

  12. Distress

    Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,9.01). Source

  13. Financings

    Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:AGEN on TradingView.

SEC filings and registration

SEC name
Agenus Inc
CIK
1098972
Industry (SIC)
Biological Products, (No Diagnostic Substances) (2836)
US tickers
AGEN (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Accelerated filer<br>Smaller reporting company
Business address
3 FORBES ROAD, LEXINGTON, MA, 02421
Phone
781-674-4410
Shares outstanding
45,020,407 as of 2026-08-04 (10-Q filed 2026-08-07)
Former names
ANTIGENICS INC /DE/

Recent filings (8-K and 6-K are the company's own announcements)

  • S-3 filed 2026-09-11
  • 8-K filed 2026-08-18
  • 8-K filed 2026-08-13
  • 8-K filed 2026-08-11
  • 10-Q filed 2026-08-07
  • S-3 filed 2026-08-07
  • 8-K filed 2026-08-06
  • S-3 filed 2026-07-20

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

Agenus Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker AGEN, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Agenus Inc.
Ticker
AGEN
Listing
NASDAQ
Country or territory
United States
Business scope
Biotechnology
ISIN
US00847G8042
Other listed symbols
BX:AGEN; GETTEX:AJ8; LSX:A403RK
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.